Talacker Augen Zentrum Zürich (TAZZ), Zürich, Switzerland.
Klin Monbl Augenheilkd. 2022 Apr;239(4):484-489. doi: 10.1055/a-1788-3967. Epub 2022 Apr 26.
To compare the efficacy and safety of core vitrectomy and pars plana vitrectomy for lens exchange in patients with intraocular lens dislocation.
This is a retrospective study conducted at one eye center in Zurich, Switzerland. We reviewed 124 eyes with dislocated intraocular lens undergoing lens exchange carried out by two surgeons between 03/2016 and 12/2019 (45 months). Intraocular pressure (IOP) and best-corrected visual acuity (BCVA) were analyzed preoperatively and at 5 time points up to 12 months after lens exchange. Data on postoperative complications were collected.
There were 124 eyes with intraocular lens dislocation that were referred for lens exchange. Of these eyes, 59 (48%) received core vitrectomy and 65 (52%) received pars plana vitrectomy with lens exchange. Glaucoma was more frequent in the core vitrectomy group (78%) than in the pars plana vitrectomy group (32%; p < 0.001). In the core vitrectomy group, 19 (32%) eyes presented with visual impairment, 17 (29%) eyes presented with high IOP alone, and 23 (39%) eyes presented with both at the same time prior to surgery. Mean preoperative IOP in the core vitrectomy group decreased from 22.4 ± 9.2 mmHg to 14.7 ± 3.1 mmHg 12 months after surgery (p < 0.001). Mean BCVA changed from 0.40 ± 0.41 logMAR preoperatively to 0.32 ± 0.37 logMAR at 12 months postoperatively (p = 0.598) in the core vitrectomy group. In the pars plana vitrectomy group, 44 (68%) eyes presented with a change in vision, 7 (11%) eyes presented with high IOP alone, and 14 (22%) eyes presented with pressure elevation and visual impairment at the visit prior to surgery. Mean preoperative IOP in the pars plana vitrectomy group decreased from 20.9 ± 8.3 mmHg to 15.1 ± 3.5 mmHg at 12 months after lens exchange (p < 0.001). Mean BCVA in the pars plana vitrectomy group was 0.57 ± 0.62 logMAR preoperatively and 0.22 ± 0.35 logMAR 12 months postoperatively (p < 0.001). Postoperative pressure decompensation occurred more frequently in the core vitrectomy group (20%) than in the pars plana vitrectomy group (6%; p = 0.018). There was no statistically significant difference for postoperative cystoid macular edema (p = 0.055), anisometropia (p = 0.986), and high astigmatism (p = 0.362).
Core vitrectomy and pars plana vitrectomy with lens exchange are equally efficient and safe in the management of intraocular lens dislocation.
比较核心玻璃体切除术和经睫状体平坦部玻璃体切除术治疗晶状体脱位患者晶状体置换的疗效和安全性。
这是在瑞士苏黎世的一个眼科中心进行的回顾性研究。我们回顾了 2016 年 3 月至 2019 年 12 月(45 个月)期间由两位外科医生进行的 124 例晶状体脱位患者的晶状体置换手术。分析了术前和术后 5 个时间点(最长 12 个月)的眼压(IOP)和最佳矫正视力(BCVA)。收集了术后并发症的数据。
共有 124 只眼因晶状体脱位而接受晶状体置换。这些眼中,59 只(48%)接受了核心玻璃体切除术,65 只(52%)接受了经睫状体平坦部玻璃体切除术联合晶状体置换术。核心玻璃体切除术组(78%)的青光眼发病率高于经睫状体平坦部玻璃体切除术组(32%;p<0.001)。在核心玻璃体切除术组中,19 只(32%)眼视力障碍,17 只(29%)眼仅眼压升高,23 只(39%)眼同时存在上述两种情况。核心玻璃体切除术组术前平均眼压从 22.4±9.2mmHg 降至术后 12 个月的 14.7±3.1mmHg(p<0.001)。核心玻璃体切除术组术前平均 BCVA 从 0.40±0.41logMAR 降至术后 12 个月的 0.32±0.37logMAR(p=0.598)。在经睫状体平坦部玻璃体切除术组中,44 只(68%)眼视力改变,7 只(11%)眼仅眼压升高,14 只(22%)眼术前眼压升高伴视力障碍。经睫状体平坦部玻璃体切除术组术前平均眼压从 20.9±8.3mmHg 降至术后 12 个月的 15.1±3.5mmHg(p<0.001)。经睫状体平坦部玻璃体切除术组术前平均 BCVA 为 0.57±0.62logMAR,术后 12 个月为 0.22±0.35logMAR(p<0.001)。核心玻璃体切除术组术后眼压减压发生率(20%)高于经睫状体平坦部玻璃体切除术组(6%;p=0.018)。术后囊样黄斑水肿(p=0.055)、屈光不正(p=0.986)和高度散光(p=0.362)差异无统计学意义。
在晶状体脱位的治疗中,核心玻璃体切除术和经睫状体平坦部玻璃体切除术联合晶状体置换术同样有效且安全。